News | September 12, 2014

University of Wisconsin Carbone Cancer Center Becomes First in the World to Treat Patients With MRIdian’s Soft-Tissue-Tracking-Beam Control

ViewRay’s MRIdian system directly tracks tumor motion continuously during treatment

University of Wisconsin Carbone Cancer Center ViewRay MRIdian

September 12, 2014 — The MRIdian system from ViewRay is now being used to treat patients at the University of Wisconsin Carbone Cancer Center in Madison, Wis., the second clinical group in the world to treat patients with magnetic resonance imaging (MRI)-guided radiation therapy. With the treatment, the center also became the first clinic in the world to employ the soft-tissue tracking beam control feature of ViewRay’s MRIdian system.

The MRIdian system is the world’s first and only MRI-guided radiation therapy system. It provides continuous imaging during treatment so clinicians are able to see where the radiation dose is being delivered and adapt to changes and movement in the patient’s anatomy in real-time. The system tracks soft-tissues of the tumor directly, in fast planar images, then automatically compares the target to the plan and only allows treatment when the target is in range.

“We had a patient with very limited treatment options,” said Michael Bassetti, M.D., Ph.D., assistant professor of radiation oncology at the University of Wisconsin Carbone Cancer Center. “The size and location of this patient’s liver tumor combined with the large observable motion prevented the safe delivery of treatment with X-Ray based linac systems. With ViewRay’s MRIdian system, we were able to ensure the accuracy of the delivery by directly tracking tumor and normal soft-tissue movement during treatment.”

The first MRI-guided radiation therapy patient at Carbone Cancer Center was a liver cancer patient who was treated with the soft-tissue tracking beam control feature employing a 5 mm margin on a breath-hold scan acquired on the system.

“I am grateful UW-Madison can now provide this remarkable treatment approach to our patients,” said John Bayouth, Ph.D., professor and chief of physics at the University of Wisconsin Carbone Cancer Center. “MRIdian enabled us to meet demanding prescription goals through its ability to track the actual tumor and surrounding normal tissues in real-time. We minimized the radiation dose to the bowel and normal liver while verifying the dose delivered to the tumor during treatment delivery.  No longer do we have to assume what is happening inside the patient during treatment, now we are able to see changes and respond accordingly.”

“We are excited to be one of the first centers to use MRI-guided radiation therapy in clinical practice,” said Paul Harari, M.D., professor and chairman of the Ddpartment of human oncology at the University of Wisconsin School of Medicine and Public Health. “Continual MR image-guidance and control is unique to the MRIdian system with the potential to change the way clinicians treat cancer patients.”

For more information:

Related Content

First Hospitals Achieve Inter-System Connectivity Across Accuray Radiation Therapy Platforms
News | Radiation Therapy | January 19, 2018
Accuray Inc. announced recently that the Heidelberg University Hospital in Heidelberg, Germany, and Oscar Lambret...
RayStation Selected for New Carbon Ion Therapy Center in Japan
News | Treatment Planning | January 18, 2018
January 18, 2018 – RayStation has been chosen as the treatment planning system for a new carbon-ion therapy facility
Raysearch Receives First Order for the Raycare Oncology Information System
News | Oncology Information Management Systems (OIMS) | January 18, 2018
January 18, 2018 – Anderson Regional Cancer Center (ARCC) in Meridian, Mississippi, has placed the first order for...
Mevion Receives 510(k) Clearance for Hyperscan Pencil Beam Scanning Proton Therapy
Technology | Proton Therapy | January 04, 2018
Mevion Medical Systems has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the Mevion S250i...
Study Compares Radiosurgery and Whole-Brain Radiation in Lung Cancer Patients With Multiple Brain Metastases
News | Radiation Therapy | January 03, 2018
Although targeted therapies have produced dramatic advances in the ability to control some types of advanced lung...
MEDraysintell Downgrades Proton Therapy Market Projection for 2030
News | Proton Therapy | January 02, 2018
MEDraysintell recently downgraded its projection for proton therapy rooms expected to be operational in 2030 from 1,200...
California US Oncology Network Centers Adopt Xoft Electronic Brachytherapy System for Early-Stage Non-Melanoma Skin Cancer
News | Brachytherapy Systems | January 02, 2018
iCAD Inc. announced that its Xoft Axxent Electronic Brachytherapy (eBx) System is now available at two California-based...
Blue Phantom System Used for Acceptance of First European Varian Halcyon Machine
News | Radiation Therapy | January 02, 2018
IBA (Ion Beam Applications S.A.) announced in November the acceptance and beam model validation of the first Varian...
Study Finds Link Between Breast Cancer Treatments and Cellular Aging Markers
News | Women's Health | January 02, 2018
January 2, 2018 — A new study found women who had received chemotherapy and/or...
ACR Appropriateness Criteria Adds and Revises Topics for December 2017
News | Clinical Decision Support | December 29, 2017
December 29, 2017 — Radiologists can enhance the quality and effectiveness of care with the newest release of the ACR
Overlay Init